Infect Chemother.  2012 Aug;44(4):213-232. 10.3947/ic.2012.44.4.213.

Clinical Practice Guidelines for Soft Tissue Infections

• The Korean Society of Infectious Diseases
• The Korean Society for Chemotherapy
• The Korean Orthopaedic Association
• The Korean Society of Clinical Microbiology
• Korean Dermatological Association

• KMID: 2045542
• DOI: http://doi.org/10.3947/ic.2012.44.4.213

Abstract

These guidelines are intended to provide practical information regarding diagnosis and management of common skin and soft tissue infections. The recommendations were developed using the best available evidence and information on antimicrobial susceptibility of major pathogens causing skin and soft tissue infections in Korea. These guidelines cover impetigo/ecthyma, furuncles/carbuncles, erysipelas, cellulitis, necrotizing fasciitis, animal bite, human bite, diabetic foot infection, and soft tissue infections in the immnocompromised host.

Keyword

Erysipelas; Cellulitis; Necrotizing fasciitis; Bite

MeSH Terms

Animals
Bites and Stings
Bites, Human
Cellulitis
Diabetic Foot
Erysipelas
Fasciitis, Necrotizing
Humans
Korea
Skin
Soft Tissue Infections

Reference

1. The Korean Society of Infectious Diseases. Korean Society for Chemotherapy. The Korean Society of Clinical Microbiology. The Korean Society of Cardiology. The Korean Society for Thoracic and Cardiovascular Surgery. Clinical guideline for the diagnosis and treatment of cardiovascular infections. Infect Chemother. 2011. 43:129–177.

2. Ferrieri P, Dajani AS, Wannamaker LW, Chapman SS. Natural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. J Clin Invest. 1972. 51:2851–2862.

3. Adams BB. Dermatologic disorders of the athlete. Sports Med. 2002. 32:309–321.

4. Fehrs LJ, Flanagan K, Kline S, Facklam RR, Quackenbush K, Foster LR. Group A beta-hemolytic streptococcal skin infections in a US meat-packing plant. JAMA. 1987. 258:3131–3134.

5. Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis. 2002. 22:42–51.

6. Darmstadt GL, Lane AT. Impetigo: an overview. Pediatr Dermatol. 1994. 11:293–303.

7. Demidovich CW, Wittler RR, Ruff ME, Bass JW, Browning WC. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child. 1990. 144:1313–1315.

8. Park JH, Byun JY, Lee DY, Lee JH, Yang JM, Lee ES. Trends of the bacterial skin infections of dermatology outpatients in 1996, 2001 and 2006. Korean J Dermatol. 2009. 47:690–695.

9. Park SW, Wang HY, Sung HS. A study for the isolation of the causative organism, antimicrobial susceptibility tests and therapeutic aspects in patients with impetigo. Korean J Dermatol. 1993. 31:312–319.

10. Kaplan EL, Wannamaker LW. Suppression of the antistreptolysin O response by cholesterol and by lipid extracts of rabbit skin. J Exp Med. 1976. 144:754–767.

11. Bisno AL, Nelson KE, Waytz P, Brunt J. Factors influencing serum antibody responses in streptococcal pyoderma. J Lab Clin Med. 1973. 81:410–420.

12. Kaplan EL, Anthony BF, Chapman SS, Ayoub EM, Wannamaker LW. The influence of the site of infection on the immune response to group A streptococci. J Clin Invest. 1970. 49:1405–1414.

13. Derrick CW Jr, Dillon HC Jr. Impetigo contagiosa. Am Fam Physician. 1971. 4:75–81.

14. Ferrieri P, Dajani AS, Wannamaker LW. A controlled study of penicillin prophylaxis against streptococcal impetigo. J Infect Dis. 1974. 129:429–438.

15. Barton LL, Friedman AD. Impetigo: a reassessment of etiology and therapy. Pediatr Dermatol. 1987. 4:185–188.

16. Dagan R, Bar-David Y. Comparison of amoxicillin and clavulanic acid (augmentin) for the treatment of nonbullous impetigo. Am J Dis Child. 1989. 143:916–918.

17. Barton LL, Friedman AD, Sharkey AM, Schneller DJ, Swierkosz EM. Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin. Pediatr Dermatol. 1989. 6:134–138.

18. Britton JW, Fajardo JE, Krafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr. 1990. 117:827–829.

19. Yun HJ, Lee SW, Yoon GM, Kim SY, Choi S, Lee YS, Choi EC, Kim S. Prevalence and mechanisms of low-and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother. 2003. 51:619–623.

20. Weinstein L, Le Frock J. Does antimicrobial therapy of streptococcal pharyngitis or pyoderma alter the risk of glomerulonephritis? J Infect Dis. 1971. 124:229–231.

21. Decker MD, Lybarger JA, Vaughn WK, Hutcheson RH Jr, Schaffner W. An outbreak of staphylococcal skin infections among river rafting guides. Am J Epidemiol. 1986. 124:969–976.

22. Sosin DM, Gunn RA, Ford WL, Skaggs JW. An outbreak of furunculosis among high school athletes. Am J Sports Med. 1989. 17:828–832.

23. Zimakoff J, Rosdahl VT, Petersen W, Scheibel J. Recurrent staphylococcal furunculosis in families. Scand J Infect Dis. 1988. 20:403–405.

24. Hedstrom SA. Recurrent staphylococcal furunculosis. Bacteriological findings and epidemiology in 100 cases. Scand J Infect Dis. 1981. 13:115–119.

25. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med. 1996. 156:1109–1112.

26. Lipsky BA, Pecoraro RE, Ahroni JH, Peugeot RL. Immediate and long-term efficacy of systemic antibiotics for eradicating nasal colonization with Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 1992. 11:43–47.

27. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA. 1988. 260:2682–2685.

28. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996. 334:240–245.

29. Chartier C, Grosshans E. Erysipelas. Int J Dermatol. 1990. 29:459–467.

30. Chartier C, Grosshans E. Erysipelas: an update. Int J Dermatol. 1996. 35:779–781.

31. Kwak YG, Kim NJ, Choi SH, Choi SH, Chung JW, Choo EJ, Kim KH, Yun NR, Lee S, Kwon KT, Cho JH. Clinical characteristics and organisms causing erysipelas and cellulitis. Infect Chemother. 2012. 44:45–50.

32. Morris AD. Cellulitis and erysipelas. Clin Evid (Online). 2008. 2008:pii: 1708.

33. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005. 41:1373–1406.

34. Bernard P, Plantin P, Roger H, Sassolas B, Villaret E, Legrain V, Roujeau JC, Rezvani Y, Scheimberg A. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol. 1992. 127:155–159.

35. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med. 2002. 346:1200–1206.

36. Seo YS, Srinivasan U, Oh KY, Shin JH, Chae JD, Kim MY, Yang JH, Yoon HR, Miller B, DeBusscher J, Foxman B, Ki M. Changing molecular epidemiology of group B streptococcus in Korea. J Korean Med Sci. 2010. 25:817–823.

37. Koh EH, Kim S, Lee NY. Decrease of erythromycin resistance in group A streptococci by change of emm distribution. Jpn J Infect Dis. 2008. 61:261–263.

38. Kim HY, Uh Y. Macrolide resistance in beta-hemolytic streptococci: changes after the implementation of the separation of prescribing and dispensing of medications policy in Korea. Yonsei Med J. 2004. 45:591–597.

39. Uh Y, Hwang GY, Jang IH, Cho HM, Noh SM, Kim HY, Kwon O, Yoon KJ. Macrolide resistance trends in beta-hemolytic streptococci in a tertiary Korean hospital. Yonsei Med J. 2007. 48:773–778.

40. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, Sassolas B, Guillaume JC, Grob JJ, Bastuji-Garin S. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999. 318:1591–1594.

41. Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med. 1982. 97:493–496.

42. Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med. 1992. 93:543–548.

43. Dankert J, Bouma J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol. 1987. 94:788–790.

44. Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM. Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol. 1989. 125:779–782.

45. Perl B, Gottehrer NP, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis. 1999. 29:1483–1488.

46. Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med. 1988. 148:2451–2452.

47. Hook EW 3rd, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med. 1986. 146:295–297.

48. Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med. 1990. 150:1907–1912.

49. Duvanel T, Auckenthaler R, Rohner P, Harms M, Saurat JH. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med. 1989. 149:293–296.

50. Woo PC, Lum PN, Wong SS, Cheng VC, Yuen KY. Cellulitis complicating lymphoedema. Eur J Clin Microbiol Infect Dis. 2000. 19:294–297.

51. Grayson ML, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull P, Chambers F. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis. 2002. 34:1440–1448.

52. Chan JC. Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Adv Ther. 1995. 12:139–146.

53. Muijsers RB, Jarvis B. Moxifloxacin in uncomplicated skin and skin structure infections. Drugs. 2002. 62:967–973. discussion 974-5.

54. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004. 164:1669–1674.

55. Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect. 1991. 22:37–40.

56. Wang JH, Liu YC, Cheng DL, Yen MY, Chen YS, Wang JH, Wann SR, Lin HH. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis. 1997. 25:685–689.

57. Sarani B, Strong M, Pascual J, Schwab CW. Necrotizing fasciitis: current concepts and review of the literature. J Am Coll Surg. 2009. 208:279–288.

58. Ellis Simonsen SM, van Orman ER, Hatch BE, Jones SS, Gren LH, Hegmann KT, Lyon JL. Cellulitis incidence in a defined population. Epidemiol Infect. 2006. 134:293–299.

59. Angoules AG, Kontakis G, Drakoulakis E, Vrentzos G, Granick MS, Giannoudis PV. Necrotising fasciitis of upper and lower limb: a systematic review. Injury. 2007. 38:Suppl 5. S19–S26.

60. Howell GM, Rosengart MR. Necrotizing soft tissue infections. Surg Infect (Larchmt). 2011. 12:185–190.

61. Cainzos M, Gonzalez-Rodriguez FJ. Necrotizing soft tissue infections. Curr Opin Crit Care. 2007. 13:433–439.

62. Morgan MS. Diagnosis and management of necrotising fasciitis: a multiparametric approach. J Hosp Infect. 2010. 75:249–257.

63. Ustin JS, Malangoni MA. Necrotizing soft-tissue infections. Crit Care Med. 2011. 39:2156–2162.

64. Cho JP, Lee WH, Hong ES, Kim DI, Cho YU, Chi HS. Necrotizing fasciitis: a clinical review. Korean J Trauma. 1993. 6:38–43.

65. Lee JH, Chi HS, Kim BR, Kim CK. Necrotizing fasciitis. J Korean Surg Soc. 1984. 27:261–269.

66. Lee ST, Lee SH, Kim KM, Lee SJ. Necrotizing fasciitis of the lower extremity. J Korean Orthop Assoc. 2005. 40:772–777.

67. Lee MW, Kim TH, Choo EJ, Kang JH, Kim DW, Kim DK, Park SW, An JH, Yoon HG, Eo SJ, Lee GW, Lee YH, Lee JY, Cheon KI. Characteristics of necrotizing fasciitis in three university hospitals in Korea. Korean J Med. 2006. 70:681–687.

68. Yang YS, Lee HU, Kim JS, Lee JK, Hong KH. A clinical study of the cervical necrotizing fasciitis. Korean J Otolaryngol-Head Neck Surg. 2005. 48:1020–1026.

69. Park JH, Park SC, Jeon HM, Jung JH, Kim WW, Oh ST, Kim JS, Kim W, Kim EK, Jang SK. Clinical analysis of Fournier's gangrene. J Korean Soc Coloproctol. 2000. 16:309–315.

70. Park YB, Shim MC, Kwun KB. Necrotizing fasciitis. J Korean Surg Soc. 1988. 35:619–625.

71. Kim KM, Seong SH, Won DY, Ryu H, Kim IY. The prognostic factors and severity index in Fournier's gangrene. J Korean Soc Coloproctol. 2010. 26:29–33.

72. Song SJ, Lee IS, Chung JH. Type I, II acute necrotizing fasciitis of the low extremity. J Korean Orthop Assoc. 2007. 42:636–643.

73. Seok JH, Jee WH, Chun KA, Kim JY, Jung CK, Kim YR, Eo WK, Kim YS, Chung YG. Necrotizing fasciitis versus pyomyositis: discrimination with using MR imaging. Korean J Radiol. 2009. 10:121–128.

74. Kim DM, Lym Y, Jang SJ, Han H, Kim YG, Chung CH, Hong SP. In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus. Antimicrob Agents Chemother. 2005. 49:3489–3491.

75. Jeong HJ, Park SC, Seo IY, Rim JS. Prognostic factors in Fournier gangrene. Int J Urol. 2005. 12:1041–1044.

76. Choi SH, Choi SH, Kwak YG, Chung JW, Choo EJ, Kim KH, Yun NR, Lee S, Kwon KT, Cho JH, Kim NJ. Clinical characteristics and causative organisms of community-acquired necrotizing fasciitis. Infect Chemother. 2012. 44:180–184.

77. Park KH, Jung SI, Jung YS, Shin JH, Hwang JH. Marine bacteria as a leading cause of necrotizing fasciitis in coastal areas of South Korea. Am J Trop Med Hyg. 2009. 80:646–650.

78. Kim ES, Song JS, Lee HJ, Choe PG, Park KH, Cho JH, Park WB, Kim SH, Bang JH, Kim DM, Park KU, Shin S, Lee MS, Choi HJ, Kim NJ, Kim EC, Oh MD, Kim HB, Choe KW. A survey of community-associated methicillin-resistant Staphylococcus aureus in Korea. J Antimicrob Chemother. 2007. 60:1108–1114.

79. Kim M, Kim NJ. Antimicrobial resistance and treatment update of skin and soft tissue infections. Korean J Med. 2011. 81:699–707.

80. Stoneback JW, Hak DJ. Diagnosis and management of necrotizing fasciitis. Orthopedics. 2011. 34:196.

81. Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis. 2005. 5:501–513.

82. Wang YS, Wong CH, Tay YK. Staging of necrotizing fasciitis based on the evolving cutaneous features. Int J Dermatol. 2007. 46:1036–1041.

83. Wysoki MG, Santora TA, Shah RM, Friedman AC. Necrotizing fasciitis: CT characteristics. Radiology. 1997. 203:859–863.

84. Becker M, Zbären P, Hermans R, Becker CD, Marchal F, Kurt AM, Marré S, Rüfenacht DA, Terrier F. Necrotizing fasciitis of the head and neck: role of CT in diagnosis and management. Radiology. 1997. 202:471–476.

85. Saldana M, Gupta D, Khandwala M, Weir R, Beigi B. Periorbital necrotizing fasciitis: outcomes using a CT-guided surgical debridement approach. Eur J Ophthalmol. 2010. 20:209–214.

86. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol. 1998. 170:615–620.

87. Hopkins KL, Li KC, Bergman G. Gadolinium-DTPA-enhanced magnetic resonance imaging of musculoskeletal infectious processes. Skeletal Radiol. 1995. 24:325–330.

88. Arslan A, Pierre-Jerome C, Borthne A. Necrotizing fasciitis: unreliable MRI findings in the preoperative diagnosis. Eur J Radiol. 2000. 36:139–143.

89. Rahmouni A, Chosidow O, Mathieu D, Gueorguieva E, Jazaerli N, Radier C, Faivre JM, Roujeau JC, Vasile N. MR imaging in acute infectious cellulitis. Radiology. 1994. 192:493–496.

90. Kim KT, Kim YJ, Won Lee J, Park SW, Lim MK, Suh CH. Can necrotizing infectious fasciitis be differentiated from non-necrotizing infectious fasciitis with MR imaging? Radiology. 2011. 259:816–824.

91. Yen ZS, Wang HP, Ma HM, Chen SC, Chen WJ. Ultrasonographic screening of clinically-suspected necrotizing fasciitis. Acad Emerg Med. 2002. 9:1448–1451.

92. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med. 2004. 32:1535–1541.

93. Tsai YH, Hsu RW, Huang KC, Huang TJ. Laboratory indicators for early detection and surgical treatment of vibrio necrotizing fasciitis. Clin Orthop Relat Res. 2010. 468:2230–2237.

94. Holland MJ. Application of the Laboratory Risk Indicator in Necrotising Fasciitis (LRINEC) score to patients in a tropical tertiary referral centre. Anaesth Intensive Care. 2009. 37:588–592.

95. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med. 1984. 310:1689–1693.

96. Majeski J, Majeski E. Necrotizing fasciitis: improved survival with early recognition by tissue biopsy and aggressive surgical treatment. South Med J. 1997. 90:1065–1068.

97. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003. 85-A:1454–1460.

98. Bilton BD, Zibari GB, McMillan RW, Aultman DF, Dunn G, McDonald JC. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg. 1998. 64:397–400. discussion 400-1.

99. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg. 1996. 224:672–683.

100. Voros D, Pissiotis C, Georgantas D, Katsaragakis S, Antoniou S, Papadimitriou J. Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection. Br J Surg. 1993. 80:1190–1191.

101. Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J. 2003. 96:968–973.

102. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999. 18:1096–1100.

103. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006. 46:741–753.

104. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE. The Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. Clin Infect Dis. 1999. 28:800–807.

105. Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis. 2003. 35:683–689.

106. Cawley MJ, Briggs M, Haith LR Jr, Reilly KJ, Guilday RE, Braxton GR, Patton ML. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy. 1999. 19:1094–1098.

107. Kaide CG, Khandelwal S. Hyperbaric oxygen: applications in infectious disease. Emerg Med Clin North Am. 2008. 26:571–595. xi

108. Demello FJ, Haglin JJ, Hitchcock CR. Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen. Surgery. 1973. 73:936–941.

109. Jallali N, Withey S, Butler PE. Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis. Am J Surg. 2005. 189:462–466.

110. Wilkinson D, Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg. 2004. 139:1339–1345.

111. Escobar SJ, Slade JB Jr, Hunt TK, Cianci P. Adjuvant hyperbaric oxygen therapy (HBO2) for treatment of necrotizing fasciitis reduces mortality and amputation rate. Undersea Hyperb Med. 2005. 32:437–443.

112. George ME, Rueth NM, Skarda DE, Chipman JG, Quickel RR, Beilman GJ. Hyperbaric oxygen does not improve outcome in patients with necrotizing soft tissue infection. Surg Infect (Larchmt). 2009. 10:21–28.

113. Shupak A, Shoshani O, Goldenberg I, Barzilai A, Moskuna R, Bursztein S. Necrotizing fasciitis: an indication for hyperbaric oxygenation therapy? Surgery. 1995. 118:873–878.

114. Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS. Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery. 1990. 108:847–850.

115. Sacks JJ, Kresnow M, Houston B. Dog bites: how big a problem? Inj Prev. 1996. 2:52–54.

116. MacBean CE, Taylor DM, Ashby K. Animal and human bite injuries in Victoria, 1998-2004. Med J Aust. 2007. 186:38–40.

117. Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJ. Emergency Medicine Animal Bite Infection Study Group. Bacteriologic analysis of infected dog and cat bites. N Engl J Med. 1999. 340:85–92.

118. Goldstein EJ. New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds. J Med Microbiol. 1998. 47:95–97.

119. Goldstein DJ, Losquadro W, Spotnitz HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin Electrophysiol. 1998. 21:1730–1734.

120. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005. 365:1333–1346.

121. Talan DA, Abrahamian FM, Moran GJ, Citron DM, Tan JO, Goldstein EJ. Emergency Medicine Human Bite Infection Study Group. Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. Clin Infect Dis. 2003. 37:1481–1489.

122. Vidmar L, Poljak M, Tomazic J, Seme K, Klavs I. Transmission of HIV-1 by human bite. Lancet. 1996. 347:1762.

123. Dusheiko GM, Smith M, Scheuer PJ. Hepatitis C virus transmitted by human bite. Lancet. 1990. 336:503–504.

124. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet. 1989. 1:889–893.

125. Fiumara NJ, Exner JH. Primary syphilis following a human bite. Sex Transm Dis. 1981. 8:21–22.

126. Lipsky BA. International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev. 2004. 20:Suppl 1. S68–S77.

127. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS. Infectious Diseases Society of America. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004. 39:885–910.

128. Lavery LA, Armstrong DG, Murdoch DP, Peters EJ, Lipsky BA. Validation of the Infectious Diseases Society of America's diabetic foot infection classification system. Clin Infect Dis. 2007. 44:562–565.

129. Slater RA, Lazarovitch T, Boldur I, Ramot Y, Buchs A, Weiss M, Hindi A, Rapoport MJ. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med. 2004. 21:705–709.

130. Sapico FL, Witte JL, Canawati HN, Montgomerie JZ, Bessman AN. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis. 1984. 6:Suppl 1. S171–S176.

131. Wheat LJ, Allen SD, Henry M, Kernek CB, Siders JA, Kuebler T, Fineberg N, Norton J. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med. 1986. 146:1935–1940.

132. Petersen PJ, Ruzin A, Tuckman M, Jones CH. In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections. Diagn Microbiol Infect Dis. 2010. 66:407–418.

133. Seo YB, Noh JY, Huh JY, Lee J, Song JY, Han SK, Kim WJ, Cheong HJ. Diabetic foot infection: microbiologic analysis based on deep tissue biopsy. Infect Chemother. 2007. 39:237–242.

134. Hartemann-Heurtier A, Robert J, Jacqueminet S, Ha Van G, Golmard JL, Jarlier V, Grimaldi A. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. Diabet Med. 2004. 21:710–715.

135. Kim H, Chung Y, Yoo BS, Kim SK, Lee KW. Anaerobic bacteria isolated from diabetic foot lesions. J Korean Diabetes Assoc. 1995. 19:305–312.

136. Ge Y, MacDonald D, Hait H, Lipsky B, Zasloff M, Holroyd K. Microbiological profile of infected diabetic foot ulcers. Diabet Med. 2002. 19:1032–1034.

137. Hunt JA. Foot infections in diabetes are rarely due to a single microorganism. Diabet Med. 1992. 9:749–752.

138. Chantelau E, Tanudjaja T, Altenhofer F, Ersanli Z, Lacigova S, Metzger C. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med. 1996. 13:156–159.

139. Hirschl M, Hirschl AM. Bacterial flora in mal perforant and antimicrobial treatment with ceftriaxone. Chemotherapy. 1992. 38:275–280.

140. Lipsky BA, Pecoraro RE, Larson SA, Hanley ME, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med. 1990. 150:790–797.

141. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol. 1999. 26:267–276.

142. Raymakers JT, Houben AJ, van der Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med. 2001. 18:229–234.

143. Duckworth C, Fisher JF, Carter SA, Newman CL, Cogburn C, Nesbit RR, Wray CH. Tissue penetration of clindamycin in diabetic foot infections. J Antimicrob Chemother. 1993. 31:581–584.

144. Kuck EM, Bouter KP, Hoekstra JB, Conemans JM, Diepersloot RJ. Tissue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections. Foot Ankle Int. 1998. 19:38–40.

145. Müller M, Brunner M, Hollenstein U, Joukhadar C, Schmid R, Minar E, Ehringer H, Eichler HG. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother. 1999. 43:2056–2058.

146. Seabrook GR, Edmiston CE, Schmitt DD, Krepel C, Bandyk DF, Towne JB. Comparison of serum and tissue antibiotic levels in diabetes-related foot infections. Surgery. 1991. 110:671–676.

147. Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C. DASIDU Steering Group. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med. 2006. 23:348–359.

148. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini JM, Kravitz SR, Landsman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV. American College of Foot and Ankle Surgeons. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg. 2006. 45:5 Suppl. S1–S66.

149. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis. 1997. 24:643–648.

150. Grayson ML, Gibbons GW, Habershaw GM, Freeman DV, Pomposelli FB, Rosenblum BI, Levin E, Karchmer AW. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994. 18:683–693.

151. Scher KS, Steele FJ. The septic foot in patients with diabetes. Surgery. 1988. 104:661–666.

152. Tan JS, Friedman NM, Hazelton-Miller C, Flanagan JP, File TM Jr. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? Clin Infect Dis. 1996. 23:286–291.

153. Piaggesi A, Schipani E, Campi F, Romanelli M, Baccetti F, Arvia C, Navalesi R. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med. 1998. 15:412–417.

154. Durham JR, McCoy DM, Sawchuk AP, Meyer JP, Schwarcz TH, Eldrup-Jorgensen J, Flanigan DP, Schuler JJ. Open transmetatarsal amputation in the treatment of severe foot infections. Am J Surg. 1989. 158:127–130.

155. Benton GS, Kerstein MD. Cost effectiveness of early digit amputation in the patient with diabetes. Surg Gynecol Obstet. 1985. 161:523–524.

156. Wade JC. Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am. 1993. 7:293–315.

157. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993. 328:1323–1332.

158. Donowitz GR. Fever in the compromised host. Infect Dis Clin North Am. 1996. 10:129–148.

159. Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infections in immunocompromised patients. Medicine (Baltimore). 1985. 64:115–133.

160. Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infection in the compromised host. Annu Rev Med. 1983. 34:205–217.

161. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002. 34:730–751.

162. Wingard JR, Santos GW, Saral R. Differences between first and subsequent fevers during prolonged neutropenia. Cancer. 1987. 59:844–849.

163. Lopez FA, Sanders CV. Dermatologic infections in the immunocompromised (non-HIV) host. Infect Dis Clin North Am. 2001. 15:671–702. xi

164. Glauser M. Empiric therapy of bacterial infections in patients with severe neutropenia. Diagn Microbiol Infect Dis. 1998. 31:467–472.

165. Goodrich JM, Reed EC, Mori M, Fisher LD, Skerrett S, Dandliker PS, Klis B, Counts GW, Meyers JD. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis. 1991. 164:731–740.

166. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011. 52:e56–e93.

167. Lee DG, Kim SH, Kim SY, Kim CJ, Park WB, Song YG, Choi JH. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011. 26:220–252.